(Q38335027)

2 September 2017

1 reference

title

Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers (English)

1 reference

2 September 2017

Anchit Khanna

1

1 reference

PubMed ID

25628223

2 September 2017

John E Pimanda

series ordinal

2

1 reference

PubMed ID

25628223

2 September 2017

language of work or name

English

0 references

publication date

13 January 2015

1 reference

International Journal of Cancer

2 September 2017

1 reference

2 September 2017

138

1 reference

2 September 2017

525-532

1 reference

2 September 2017

3

1 reference

Regulation of cell adhesion by PP2A and SV40 small tumor antigen: an important link to cell transformation

2 September 2017

1 reference

Involvement of PP2A in viral and cellular transformation

21 January 2018

1 reference

Identification of PP2A complexes and pathways involved in cell transformation

21 January 2018

1 reference

Multiple pathways regulated by the tumor suppressor PP2A in transformation

21 January 2018

1 reference

The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells

21 January 2018

1 reference

Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence

21 January 2018

1 reference

A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins

21 January 2018

1 reference

Phosphatases: providing safe passage through mitotic exit

21 January 2018

1 reference

Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.

21 January 2018

1 reference

Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands

21 January 2018

1 reference

CIP2A inhibits PP2A in human malignancies

21 January 2018

1 reference

Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.

21 January 2018

1 reference

MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

21 January 2018

1 reference

ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells

21 January 2018

1 reference

Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.

21 January 2018

1 reference

CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes

21 January 2018

1 reference

Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells

21 January 2018

1 reference

Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation.

21 January 2018

1 reference

CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice

21 January 2018

1 reference

Prognostic role of CIP2A expression in serous ovarian cancer

21 January 2018

1 reference

CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis

21 January 2018

1 reference

CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis

21 January 2018

1 reference

CIP2A overexpression is associated with c-Myc expression in colorectal cancer.

21 January 2018

1 reference

CIP2A is a predictor of poor prognosis in colon cancer.

21 January 2018

1 reference

CIP2A influences survival in colon cancer and is critical for maintaining Myc expression

21 January 2018

1 reference

CIP2A is associated with human breast cancer aggressivity

21 January 2018

1 reference

Clinical implications of CIP2A protein expression in breast cancer

21 January 2018

1 reference

Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis

21 January 2018

1 reference

CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis.

21 January 2018

1 reference

Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues.

21 January 2018

1 reference

CIP2A expression is elevated in cervical cancer

21 January 2018

1 reference

Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein

21 January 2018

1 reference

CIP2A protein expression in high-grade, high-stage bladder cancer

21 January 2018

1 reference

CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma

21 January 2018

1 reference

CIP2A expression is increased in prostate cancer

21 January 2018

1 reference

Expression and prognostic significance of CIP2A in cutaneous malignant melanoma

21 January 2018

1 reference

Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.

21 January 2018

1 reference

CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion

21 January 2018

1 reference

High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer

21 January 2018

1 reference

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.

21 January 2018

1 reference

Mutational analysis of MYC in common epithelial cancers and acute leukemias.

21 January 2018

1 reference

Modelling Myc inhibition as a cancer therapy

21 January 2018

1 reference

c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle

21 January 2018

1 reference

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

21 January 2018

1 reference

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

21 January 2018

1 reference

Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells

21 January 2018

1 reference

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

21 January 2018

1 reference

CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle

21 January 2018

1 reference

Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.

21 January 2018

1 reference

Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition.

21 January 2018

1 reference

Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome

21 January 2018

1 reference

Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells

21 January 2018

1 reference

CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells

21 January 2018

1 reference

CIP2A is a target of bortezomib in human triple negative breast cancer cells

21 January 2018

1 reference

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

21 January 2018

1 reference

Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types

21 January 2018

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.

21 January 2018

1 reference

Increase in CIP2A expression is associated with doxorubicin resistance.

21 January 2018

1 reference

Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells

21 January 2018

1 reference

Therapy-induced senescence in cancer

21 January 2018

1 reference

Pro-senescence therapy for cancer treatment

21 January 2018

1 reference

Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma

21 January 2018

1 reference

CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer.

21 January 2018

1 reference

Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29431

1 reference

2 September 2017

1 reference

PubMed ID

25628223